Frank S. Chen

Array ( [id] => 19297746 [patent_doc_number] => 20240226312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA [patent_app_type] => utility [patent_app_number] => 18/566832 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -161 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343708 [patent_doc_number] => 20240252671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/566805 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20608325 [patent_doc_number] => 12583913 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-24 [patent_title] => Antibody specific to [patent_app_type] => utility [patent_app_number] => 17/746660 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 53 [patent_no_of_words] => 13692 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17746660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18194725 [patent_doc_number] => 20230048244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/745456 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17745456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302457 [patent_doc_number] => 12448435 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Anti-TMPRSS6 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/741234 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 29379 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 285 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17741234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20663712 [patent_doc_number] => 12605462 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-21 [patent_title] => Porous silicon nanoparticle-based drug delivery system inducing reactive oxygen species and self-activation thereof, and method for preparing same [patent_app_type] => utility [patent_app_number] => 17/739616 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 31 [patent_no_of_words] => 4230 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554970 [patent_doc_number] => 20240366762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => CHIMERIC FC-ALPHA RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/557697 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18557697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246924 [patent_doc_number] => 20240197908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => MODIFIED EXTRACELLULAR VESICLES (EVS) WITH IMPROVED HALF-LIFE [patent_app_type] => utility [patent_app_number] => 18/287206 [patent_app_country] => US [patent_app_date] => 2022-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20295049 [patent_doc_number] => 20250320292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-16 [patent_title] => KIDNEY-GLOMERULAR TARGETED IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/556216 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096479 [patent_doc_number] => 20240115706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => GUCY2C BINDING POLYPEPTIDE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/553391 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157759 [patent_doc_number] => 20240150466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => ANTI-IGFBP7 CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/282201 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720456 [patent_doc_number] => 20220213176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => ANTIBODIES AGAINST SARS-COV-2 SPIKE PROTEIN [patent_app_type] => utility [patent_app_number] => 17/702710 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19416 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20231353 [patent_doc_number] => 20250288672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-18 [patent_title] => HUMANIZED SYNTHETIC NOTCH RECEPTORS WITH AUGMENTED TRANSACTIVATION DOMAINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/551935 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18551935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19171000 [patent_doc_number] => 20240156974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/282432 [patent_app_country] => US [patent_app_date] => 2022-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554874 [patent_doc_number] => 20240366666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => METHODS AND COMPOSITIONS FOR ENHANCING THE CYTOTOXICITY OF GAMMA/DELTA-T CELLS [patent_app_type] => utility [patent_app_number] => 18/553947 [patent_app_country] => US [patent_app_date] => 2022-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6353 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097804 [patent_doc_number] => 20240117032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => NOVEL AFFINITY CONSTRUCTS AND METHODS FOR THEIR USE [patent_app_type] => utility [patent_app_number] => 18/259635 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -100 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127227 [patent_doc_number] => 20240132580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => VEGFA-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/277749 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127227 [patent_doc_number] => 20240132580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => VEGFA-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/277749 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627288 [patent_doc_number] => 20220162303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => COMPOSITIONS AND METHODS FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 17/669800 [patent_app_country] => US [patent_app_date] => 2022-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17669800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081852 [patent_doc_number] => 20240108653 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING WITH CAR CELLS [patent_app_type] => utility [patent_app_number] => 18/275921 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275921 [rel_patent_id] =>[rel_patent_doc_number] =>)